Apolipoprotein E2 accentuates postprandial inflammation and diet-induced obesity to promote hyperinsulinemia in mice

Diabetes

Volumn 62, Issue 2, 2013, Pages 382-391

  Kuhel, David G ^a   Konaniah, Eddy S ^a   Basford, Joshua E ^a   McVey, Courtney ^a   Goodin, Colleen T ^a   Chatterjee, Tapan K ^a   Weintraub, Neal L ^a   Hui, David Y ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; INSULIN; LIPID;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL DIET; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; GRANULOCYTE; HYPERINSULINEMIA; HYPERLIPIDEMIA; INFLAMMATION; LIPID DIET; MALE; METABOLIC DISORDER; MOUSE; NEUTROPHIL; NONHUMAN; OBESITY; PLASMA CLEARANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN STRUCTURE;

ADIPOCYTES; ADIPOSE TISSUE; ADIPOSITY; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; FASTING; GRANULOCYTES; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OBESITY; POSTPRANDIAL PERIOD;

EID: 84873020587     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0390     Document Type: Article

References (44)

1. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009;50(Suppl.):S183-S188
2. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res 2009;50(Suppl.):S156- S161
3. Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet 1986;29:477-484
4. Duman BS, Oztürk M, Yilmazer S, Hatemi H. Apolipoprotein E polymorphism in Turkish subjects with type 2 diabetes mellitus: allele frequency and relation to serum lipid concentrations. Diabetes Nutr Metab 2004;17:267-274
5. Zeggini E, Weedon MN, Lindgren CM, et al.; Wellcome Trust Case Control Consortium (WTCCC). Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-1341
6. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-1345
7. Saxena R, Voight BF, Lyssenko V, et al.; Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316: 1331-1336
8. Zeggini E, Scott LJ, Saxena R, et al.; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40:638-645
9. Zeljko HM, Škarić-Jurić T, Narancić NS, et al. E2 allele of the apolipo-protein E gene polymorphism is predictive for obesity status in Roma minority population of Croatia. Lipids Health Dis 2011;10:9
10. Anthopoulos PG, Hamodrakas SJ, Bagos PG. Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol Genet Metab 2010;100:283-291
11. Kalix B, Meynet MC, Garin MC, James RW. The apolipoprotein e2 allele and the severity of coronary artery disease in type 2 diabetic patients. Diabet Med 2001;18:445-450
12. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T. The presence of apolipoprotein e4 and e2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 2007;40:1150-1156
13. Oda H, Yorioka N, Ueda C, Kushihata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl 1999;71:S25-S27
14. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fermanian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease. A case-control study. Stroke 1993;24:661-664
15. Sentí M, Nogués X, Pedro-Botet J, Rubiés-Prat J, Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992;85:30-36
16. de Andrade M, Thandi I, Brown S, Gotto A Jr, Patsch W, Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet 1995;56:1379-1390
17. Hui DY, Innerarity TL, Mahley RW. Defective hepatic lipoprotein receptor binding of b-very low density lipoproteins from type III hyper-lipoproteinemic patients. Importance of apolipoprotein E. J Biol Chem 1984;259:860-869
18. Higgins LJ, Rutledge JC. Inflammation associated with the postprandial lipolysis of triglyceride-rich lipoproteins by lipoprotein lipase. Curr Atheroscler Rep 2009;11:199-205
19. Gower RM, Wu H, Foster GA, et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011; 31:160-166
20. Alipour A, van Oostrom AJHHM, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-797
21. Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53:701-710
22. Harbis A, Perdreau S, Vincent-Baudry S, et al. Glycemic and insulinemic meal responses modulate postprandial hepatic and intestinal lipoprotein accumulation in obese, insulin-resistant subjects. Am J Clin Nutr 2004;80: 896-902
23. Rivellese AA, Bozzetto L, Annuzzi G. Postprandial lipemia, diet, and cardiovascular risk. Curr Cardiovasc Risk Rep 2009;3:5-11
24. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe&z.ast;2. J Clin Invest 1998; 102:130-135
25. Sullivan PM, Mezdour H, Aratani Y, et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997;272:17972-17980
26. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548
27. Hofmann SM, Zhou L, Perez-Tilve D, et al. Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J Clin Invest 2007;117:3271-3282
28. Hofmann SM, Perez-Tilve D, Greer TM, et al. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipo-protein E-deficient mice. Diabetes 2008;57:5-12
29. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46:2347-2355
30. van Oostrom AJHHM, Sijmonsma TP, Verseyden C, et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 2003;44:576-583
31. Drechsler M, Megens RTA, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010;122:1837-1845
32. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219-246
33. den Hartigh LJ, Connolly-Rohrbach JE, Fore S, Huser TR, Rutledge JC. Fatty acids from very low-density lipoprotein lipolysis products induce lipid droplet accumulation in human monocytes. J Immunol 2010;184:3927-3936
34. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009;297:E271-E288
35. Goudriaan JR, Tacken PJ, Dahlmans VEH, et al. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001;21:1488-1493
36. Wilsie LC, Chanchani S, Navaratna D, Orlando RA. Cell surface heparan sulfate proteoglycans contribute to intracellular lipid accumulation in adipocytes. Lipids Health Dis 2005;4:2
37. Huang Y, Liu XQ, Rall SC Jr, Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem 1998;273:17483-17490
38. Huang ZH, Maeda N, Mazzone T. Expression of the human apoE2 isoform in adipocytes: altered cellular processing and impaired adipocyte lipo-genesis. J Lipid Res 2011;52:1733-1741
39. Ruiz J, Kouiavskaia D, Migliorini M, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res 2005;46:1721-1731
40. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341:162-164
41. Takahashi S, Oida K, Ookubo M, et al. Very low density lipoprotein receptor binds apolipoprotein E2/2 as well as apolipoprotein E3/3. FEBS Lett 1996;386:197-200
42. Futamura M, Dhanasekaran P, Handa T, Phillips MC, Lund-Katz S, Saito H. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate pro-teoglycan complex formation on cell surfaces. J Biol Chem 2005;280:5414-5422
43. Ji ZS, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. J Biol Chem 1998;273:13452-13460
44. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci USA 2003; 100:3077-3082